In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
from News Medical Medical Research News Feed https://ift.tt/2VORlUi
0 Comments